Clinical Trial Search

Primary: Number of Telehealth and Non-Telehealth LARC Device Initiations Within the SBHC Network — 4; 73 device initiations

Primary: GMC of Anti-measles Antibodies at Day 43 — 801; 788; 728; 682 mIU/mL

Primary: Primary Safety Endpoint - Change in HbA1c — -0.2; -0.4 Percentage of HbA1c — p=<0.001

Primary: Change in Modified Rankin Scale at 12 Weeks — -0.44; -0.50 units on a scale — p=0.896

Primary: Change From Baseline in Appetite Hormones PYY — 58.5; 60; 56 mmol/L*min

Primary: MATRICS Consensus Cognitive Battery (MCCB) — 41.8; 39.67 units on a scale

Primary: Acute Care Admission — 0.644; 0.613 Proportion of participants

Primary: To Assess the Anti-infective Efficacy of D-PLEX Over a Period of 30 Days Post Operation, by Preventing Surgical Site Infection (SSI), Defined as Superficial and Deep…

Primary: Relaxin (RLX) Levels — NA; NA; NA; NA pmol/mL

Primary: Baseline Neural Flavor Cue-reactivity at Baseline — 0.08; 0.23; 0.10; 0.14 percentage of BOLD signal change

Primary: Number of Participants With Independent Functioning on the Modified Rankin Scale (mRS), as Defined by a Score of 0-2 — 181; 206 Participants

Primary: Number of Participants With Adverse Events (AEs) — 56 Participants

Primary: Number of Participants Experiencing Adverse Events (AEs) - Part 1 — 16; 14; 18; 12 Participants

Primary: Maximum Tolerated Dose (MTD) of Xentuzumab in Japanese Patients With Advanced Solid Tumours, as Identified by the Number of Patients With Dose-limiting Toxicities (DLTs)…

Primary: Therapist Negative Beliefs About Exposure Scale (TBES) — 28.76; 30.9; 21.19; 21.2 score on a scale